{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:55:33Z","timestamp":1783734933766,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012186","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000}}],"reference-count":428,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012186.pub2","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T12:41:25Z","timestamp":1701348085000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Irene","family":"Tramacere","sequence":"additional","affiliation":[{"name":"Department of Research and Clinical Development, Scientific Directorate; Fondazione IRCCS Istituto Neurologico Carlo Besta; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy"},{"name":"Ophthalmology; IRCCS \u2013 Fondazione Bietti; Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Perduca","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, CNRS; MAP5; F-75006 Paris France"},{"name":"Universit\u00e9 Paris-Saclay, UVSQ, Inserm, Gustave Roussy; CESP; 94805, Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[{"name":"Department of Statistics, Computer Science and Applications \"G. Parenti\"; University of Florence; Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Donata","family":"Benedetti","sequence":"additional","affiliation":[{"name":"UOC Neurologia B - Policlinico Borgo Roma; Azienda Ospedaliera Universitaria Integrata; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Capobussi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health; University of Milan; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Castellini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health; University of Milan; Milan Italy"},{"name":"Unit of Clinical Epidemiology; IRCCS Galeazzi Orthopaedic Institute; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Frau","sequence":"additional","affiliation":[{"name":"Brighton and Hove UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marien","family":"Gonzalez-Lorenzo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health; University of Milan; Milan Italy"},{"name":"Department of Oncology, Laboratory of Clinical Research Methodology; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Featherstone","sequence":"additional","affiliation":[{"name":"Evidence Production and Methods Directorate; Cochrane; Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[{"name":"Scientific Director\u2019s Office; Carlo Besta Foundation and Neurological Institute; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","article-title":"Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses","volume":"50","author":"Achiron","year":"1998","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","article-title":"Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiplesclerosis: a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Achiron","year":"2004","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"The Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0004|cit4","unstructured":"Efficacy and safety study of Peginterferon beta-1a in participants with relapsing multiple sclerosis (ADVANCE) clinicaltrials.gov\/show\/NCT00906399"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2015.06.004","article-title":"Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis","volume":"4","author":"Newsome","year":"2015","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.msard.2014.08.005","article-title":"Natalizumab reduces relapse clinical severity and improves relapse recovery in MS","volume":"3","author":"Lublin","year":"2014","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0007|cit7","unstructured":"Safety and efficacy of natalizumab in the treatment of multiple sclerosis clinicaltrials.gov\/show\/NCT00027300"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012186.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","article-title":"Placebo-controlled trial of oral laquinimod for multiple sclerosis","volume":"366","author":"Comi","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0010|cit10","unstructured":"Safety and efficacy of orally administered laquinimod versus placebo for treatment of relapsing remitting multiple sclerosis (RRMS) (ALLEGRO) clinicaltrials.gov\/show\/NCT00509145"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/jnnp.2003.010090","article-title":"Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis","volume":"75","author":"Andersen","year":"2004","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"205521731986497","DOI":"10.1177\/2055217319864974","article-title":"Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension","volume":"5","author":"Kondo","year":"2019","journal-title":"Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jns.2017.08.2241","article-title":"Efficacy and safety of delayed-release dimethyl fumarate in treatment-na\u00efve Japanese patients with relapsing-remitting multiple sclerosis: A post-hoc subgroup analysis of the APEX study","volume":"381","author":"Mori","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0014|cit14","first-page":"457","article-title":"Efficacy and safety of dimethyl fumarate in Japanese MS patients who had the history of treatment with fingolimod: APEX part 1+2 interim analysis","volume":"25","author":"Mori","year":"2019","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"205521731985272","DOI":"10.1177\/2055217319852727","article-title":"Efficacy and safety of dimethyl fumarate in treatment-na\u00efve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study","volume":"5","author":"Mori","year":"2019","journal-title":"Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0016|cit16","unstructured":"An efficacy and safety study of BG00012 (dimethyl fumarate) in Asian subjects with relapsing remitting multiple sclerosis (RRMS) clinicaltrials.gov\/show\/NCT01838668"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s12325-018-0788-8","article-title":"72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension","volume":"35","author":"Ochi","year":"2018","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"5. Appendix 1;","DOI":"10.1186\/s12883-018-1220-3","article-title":"A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries","volume":"19","author":"Saida","year":"2019","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Kira JI Nakahara J Sazonov DV Kurosawa T Tsumiyama I Willi R Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study Multiple sclerosis (Houndmills, Basingstoke, England) 2022 28 8 1229 38. Supplemental material [Figure e-1; Table e-1]","DOI":"10.1177\/13524585211055934"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0020|cit20","unstructured":"Efficacy and safety of ofatumumab compared to placebo in patients with relapsing multiple sclerosis followed by extended treatment with open-label ofatumumab clinicaltrials.gov\/show\/NCT03249714"},{"issue":"15 Supplement","key":"10.1002\/14651858.CD012186.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S8.003","DOI":"10.1212\/WNL.90.15_supplement.S8.003","article-title":"Arpeggio: a placebo-controlled trial of oral laquinimod in primary progressive multiple sclerosis","volume":"90","author":"Giovannoni","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD012186.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000010284","article-title":"A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis","volume":"95","author":"Giovannoni","year":"2020","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0023|cit23","unstructured":"A phase 2 clinical study in subjects with primary progressive multiple sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg\/day or 1.5mg\/day (experimental drug) as compared to placebo (ARPEGGIO) clinicaltrials.gov\/show\/NCT02284568"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"A713","DOI":"10.1016\/j.jval.2015.09.2688","article-title":"Measuring the impact of secondary progressive multiple sclerosis (Spms) in the Ascend trial: equating the Msis-29, Msws-12, Abilhand-56 and Sf-36","volume":"18","author":"Cano","year":"2015","journal-title":"Value Health"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0026|cit26","unstructured":"A clinical study of the efficacy of natalizumab on reducing disability progression in participants with secondary progressive multiple sclerosis (ASCEND in SPMS) clinicaltrials.gov\/show\/NCT01416181"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0028|cit28","unstructured":"Efficacy and safety of Ofatumumab compared to Teriflunomide in patients with relapsing multiple sclerosis (ASCLEPIOS I) clinicaltrials.gov\/show\/NCT02792218"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0030|cit30","unstructured":"Efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing multiple sclerosis. (ASCLEPIOS II) clinicaltrials.gov\/show\/NCT02792231"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0031|cit31","first-page":"457","article-title":"Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon \u03b2-1\u03b1: A randomized controlled trial","volume":"16","author":"Savoj","year":"2011","journal-title":"Journal of Research in Medical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0032|cit32","first-page":"1","article-title":"Efficacy and safety of 2 fingolimod doses vs glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"78","author":"Cree","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0033|cit33","unstructured":"MS study evaluating safety and efficacy of two doses of fingolimod versus copaxone (ASSESS) clinicaltrials.gov\/show\/NCT01633112"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0034|cit34","unstructured":"International Conference on Harmonisation (ICH GCP) The AVANTAGE study - A randomized, multicenter, phase iv, open-label prospective study comparing injection site reaction and injection site pain in patients with relapsing remitting multiple sclerosis (RRMS) or after a first demyelinating event suggestive of MS newly started on interferon beta-1b (Betaferon\u00ae) or interferon beta-1a (Rebif\u00ae) https:\/\/ichgcp.net\/clinical-trials-registry\/NCT00317941 (accessed 6 June 2022) 2013"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0035|cit35","unstructured":"Safety study in relapsing-remitting multiple sclerosis (RRMS) patients receiving Betaferon or Rebif ClinicalTrials.gov: NCT00317941"},{"issue":"23","key":"10.1002\/14651858.CD012186.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000345970.73354.17","article-title":"Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study","volume":"72","author":"Cadavid","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0037|cit37","unstructured":"Phase IV study, betaseron versus copaxone for relapsing remitting or CIS forms of MS using triple dose Gad 3 T MRI (BECOME) clinicaltrials.gov\/show\/NCT00176592"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0039|cit39","unstructured":"BEYOND: Betaferon\/Betaseron efficacy yielding outcomes of a new dose in multiple sclerosis (MS) patients clinicaltrials.gov\/show\/NCT00099502"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O'Connor","year":"2009","journal-title":"Lancet Neurology"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s00415-016-8146-8","article-title":"Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial","volume":"263","author":"Schippling","year":"2016","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0042|cit42","unstructured":"Safety, tolerability, efficacy and optimal dose finding study of BAF312 in patients with relapsing-remitting multiple sclerosis ClinicalTrials.gov: NCT00879658"},{"issue":"8","key":"10.1002\/14651858.CD012186.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"The Lancet. Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Bornstein MB Miller A Slagle S Weitzman M Drexler E A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis New England Journal of Medicine 1987 317 7 408 14","DOI":"10.1056\/NEJM198708133170703"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1212\/WNL.41.4.533","article-title":"A placebo-controlled, double-blind, randomised, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis","volume":"41","author":"Bornstein","year":"1991","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.17116\/jnevro201611610261-67","article-title":"Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study","volume":"116","author":"Boyko","year":"2016","journal-title":"Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0047|cit47","unstructured":"Efficacy and safety of BCD-063 and Copaxone-Teva in patients with relapsing-remitting multiple sclerosis ClinicalTrials.gov\/show\/NCT02753088"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.17116\/jnevro201711722107-113","article-title":"A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations","volume":"117","author":"Boyko","year":"2017","journal-title":"Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006264.pub2","article-title":"Corticosteroids for the long-term treatment in multiple sclerosis","author":"Ciccone","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0050|cit50","unstructured":"BRAVO study: Laquinimod double blind placebo controlled study in RRMS patients with a rater blinded reference arm of Interferon \u03b2-1a (Avonex\u00ae) (BRAVO) clinicaltrials.gov\/show\/NCT00605215"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0051|cit51","first-page":"84","article-title":"Effect of laquinimod on gray matter and white matter atrophy in relapsing-remitting multiple sclerosis: Analysis of the BRAVO phase III trial","volume":"20","author":"Nakamura","year":"2014","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","article-title":"A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis","volume":"261","author":"Vollmer","year":"2014","journal-title":"Journal of Neurology"},{"issue":"8604","key":"10.1002\/14651858.CD012186.pub2-BIB0053|cit53","first-page":"179","article-title":"Double-masked trial of azathioprine in multiple sclerosis","volume":"2","author":"The British and Dutch","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/1352458510394702","article-title":"Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis","volume":"18","author":"Calabrese","year":"2012","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"17","key":"10.1002\/14651858.CD012186.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"CAMMS223","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jns.2016.02.025","article-title":"ALEMTUZUMAB improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients","volume":"363","author":"Fox","year":"2016","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0057|cit57","unstructured":"A phase II study comparing low- and high-dose alemtuzumab and high-dose Rebif\u00ae in patients with early, active relapsing-remitting multiple sclerosis clinicaltrials.gov\/show\/NCT00050778"},{"issue":"14","key":"10.1002\/14651858.CD012186.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1212\/WNL.0000000000003169","article-title":"Superior MRI outcomes with ALEMTUZUMAB compared with subcutaneous INTERFERON beta-1a in MS","volume":"87","author":"Arnold","year":"2016","journal-title":"Neurology"},{"issue":"9856","key":"10.1002\/14651858.CD012186.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0060|cit60","first-page":"106","article-title":"Alemtuzumab reduces disease activity in treatment naive patients with highly active relapsing-remitting multiple sclerosis","volume":"20","author":"Krieger","year":"2014","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0061|cit61","first-page":"83","article-title":"Improvement in MRI outcomes across subgroups with alemtuzumab versus interferon beta-1a in treatment naive relapsing-remitting multiple sclerosis","volume":"20","author":"Montalban","year":"2014","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0062|cit62","unstructured":"Comparison of Alemtuzumab and Rebif\u00ae efficacy in multiple sclerosis, study one (CARE-MS I) clinicaltrials.gov\/show\/NCT00530348"},{"issue":"9856","key":"10.1002\/14651858.CD012186.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0064|cit64","unstructured":"Comparison of alemtuzumab and Rebif\u00ae efficacy in multiple sclerosis, study two (CARE-MS II) clinicaltrials.gov\/show\/NCT00548405"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0065|cit65","first-page":"419","article-title":"Defining clinical meaning of patient-reported outcomes with disability assessment in multiple sclerosis: An analysis of the CARE-MS II study","volume":"20","author":"Steinman","year":"2014","journal-title":"Multiple Sclerosis"},{"issue":"8739","key":"10.1002\/14651858.CD012186.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(91)93389-Q","article-title":"The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis","volume":"337","year":"1991","journal-title":"Lancet"},{"issue":"13","key":"10.1002\/14651858.CD012186.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group","volume":"343","author":"Jacobs","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/ane.13344","article-title":"Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial","volume":"143","author":"Cheshmavar","year":"2021","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0069|cit69","unstructured":"Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients clinicaltrials.gov\/show\/NCT03315923"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0071|cit71","first-page":"599","article-title":"Infections during periods of grade 3 or 4 lymphopenia in patients taking CLADRIBINE tablets 3.5 mg\/kg: Data from an integrated safety analysis","volume":"23","author":"Cook","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0074|cit74","unstructured":"A safety and efficacy study of oral cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS) (CLARITY) clinicaltrials.gov\/show\/NCT00213135"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0075|cit75","first-page":"S146","article-title":"Consistent efficacy of short-course CLAdRIbine tablets therapy across differing prognostic indicators for relapsing-remitting multiple sclerosis: Results from the phase III, double-blind, placebo-controlled, 96-week CLARITY study","volume":"16","author":"Rammohan","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0076|cit76","first-page":"S21","article-title":"Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: Results from the phase III, 96-week CLARITY study","volume":"258","author":"Rammohan","year":"2011","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.msard.2011.08.006","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study","volume":"1","author":"Rammohan","year":"2012","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0078|cit78","first-page":"56","article-title":"Consistent efficacy of cladribine tablets across the spectrum of patients with relapsing-remitting multiple sclerosis of differing severity: Data from the 96-week, double-blind CLARITY study","volume":"17","author":"Rieckmann","year":"2010","journal-title":"European Journal of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0079|cit79","first-page":"1283","article-title":"Efficacy of short-course oral therapy with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study","volume":"16","author":"Rieckmann","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0080|cit80","first-page":"S48","article-title":"Exploring correlations between changes in lymphocyte counts and clinical\/magnetic resonance imaging outcomes in cladribine-treated patients with relapsing-remitting multiple sclerosis: Analyses from the double blind, 96-week CLARITY study","volume":"258","author":"Rieckmann","year":"2011","journal-title":"Journal of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0081|cit81","first-page":"S298","article-title":"Tolerability and retention on treatment with cladribine tablets for relapsing-remitting multiple sclerosis over 96 weeks in the phase III, double-blind, placebo-controlled CLARITY study","volume":"16","author":"Vermersch","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0082|cit82","first-page":"S259","article-title":"Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: Factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study","volume":"258","author":"Vermersch","year":"2011","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.msard.2012.01.006","article-title":"The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics","volume":"1","author":"Lindsey","year":"2012","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.23863","article-title":"Randomized study combining interferon and glatiramer acetate in multiple sclerosis","volume":"73","author":"Lublin","year":"2013","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0085|cit85","unstructured":"Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx clinicaltrials.gov\/show\/NCT00211887"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","article-title":"European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European\/Canadian Glatiramer Acetate Study Group","volume":"49","author":"Comi","year":"2001","journal-title":"Annals of Neurology"},{"issue":"9630","key":"10.1002\/14651858.CD012186.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(08)60918-6","article-title":"Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"371","author":"Comi","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0088|cit88","unstructured":"A study to evaluate the effectiveness, tolerability and safety of laquinimod clinicaltrials.gov\/show\/NCT00349193"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/13524585211032803","article-title":"CONCERTO: a randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis","volume":"28","author":"Comi","year":"2022","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0090|cit90","unstructured":"The efficacy, safety, and tolerability of Laquinimod in participants with relapsing remitting multiple sclerosis (RRMS) (CONCERTO) clinicaltrials.gov\/show\/NCT01707992"},{"issue":"12","key":"10.1002\/14651858.CD012186.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012186.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.0000000000001360","article-title":"Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study","volume":"84","author":"Miller","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0093|cit93","unstructured":"Efficacy and safety study of oral BG00012 with active reference in relapsing-remitting multiple sclerosis (CONFIRM) clinicaltrials.gov\/show\/NCT00451451"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/1352458517707345","article-title":"Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with Daclizumab beta: Results from the DECIDE study","volume":"24","author":"Benedict","year":"2018","journal-title":"Multiple Sclerosis"},{"issue":"15","key":"10.1002\/14651858.CD012186.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","article-title":"Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis","volume":"373","author":"Kappos","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s12325-016-0353-2","article-title":"Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis","volume":"33","author":"Krueger","year":"2016","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0097|cit97","unstructured":"Efficacy and safety of BIIB019 (daclizumab high yield process) versus interferon \u03b2 1a in participants with relapsing-remitting multiple sclerosis (DECIDE) clinicaltrials.gov\/show\/NCT01064401"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"175628642091500","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0099|cit99","first-page":"313","article-title":"Efficacy of delayed-release dimethyl FUMARATE in newly diagnosed patients with relapsing-remitting multiple sclerosis: Eight-year follow-up of an integrated analysis of DEFINE, CONFIRM, and ENDORSE","volume":"23","author":"Gold","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"12","key":"10.1002\/14651858.CD012186.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0101|cit101","unstructured":"Efficacy and safety of oral BG00012 in relapsing-remitting multiple sclerosis (DEFINE) clinicaltrials.gov\/show\/NCT00420212"},{"issue":"8","key":"10.1002\/14651858.CD012186.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.39.8.1018","article-title":"A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis","volume":"39","author":"Ellison","year":"1989","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1600-0404.2006.00585.x","article-title":"Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis","volume":"113","author":"Etemadifar","year":"2006","journal-title":"Acta Neurologica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD012186.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00415-007-0637-1","article-title":"Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis","volume":"254","author":"Etemadifar","year":"2007","journal-title":"Journal of Neurology"},{"issue":"9268","key":"10.1002\/14651858.CD012186.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Early Treatmentof Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"issue":"9139","key":"10.1002\/14651858.CD012186.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS","volume":"352","author":"European SG","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD012186.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1212\/WNL.57.11.1969","article-title":"Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS","volume":"57","author":"Kappos","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2017.05.052","article-title":"Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon \u03b2-1a in the EVIDENCE study","volume":"379","author":"Coyle","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0109|cit109","unstructured":"A study of Rebif\u00ae compared with Avonex\u00ae in the treatment of relapsing-remitting multiple sclerosis (MS) ClinicalTrials.gov\/show\/NCT00292266"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","article-title":"Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial","volume":"59","author":"Panitch","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.clinthera.2007.09.025","article-title":"Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis","volume":"29","author":"Schwid","year":"2007","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0112|cit112","unstructured":"A tolerability study of ALKS 8700 in subjects with relapsing remitting multiple sclerosis (RRMS) EVOLVE-MS-2 clinicaltrials.gov\/show\/NCT03093324"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study","volume":"34","author":"Naismith","year":"2020","journal-title":"CNS Drugs"},{"issue":"10127","key":"10.1002\/14651858.CD012186.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0115|cit115","unstructured":"Exploring the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (EXPAND) clinicaltrials.gov\/show\/NCT01665144"},{"issue":"9052","key":"10.1002\/14651858.CD012186.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","article-title":"Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis","volume":"349","author":"Fazekas","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0119|cit119","unstructured":"Efficacy and safety of Fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS) clinicaltrials.gov\/show\/NCT00289978"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0121|cit121","unstructured":"Efficacy and safety of fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis (FREEDOMS II) clinicaltrials.gov\/show\/NCT00355134"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0122|cit122","first-page":"112","article-title":"Effect of fingolimod on evolution of baseline enhancing MRI lesions into persistent T1 hypointense lesions: Post hoc analysis of the FREEDOMS study","volume":"20","author":"Radue","year":"2014","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"e1037","DOI":"10.1212\/NXI.0000000000001037","article-title":"Dimethyl fumarate treatment in patients with primary progressive multiple sclerosis: a randomized, controlled trial","volume":"8","author":"H\u00f8jsgaard Chow","year":"2021","journal-title":"Neurology (R) Neuroimmunology & Neuroinflammation"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0124|cit124","unstructured":"Dimethyl fumarate treatment of primary progressive multiple sclerosis (FUMAPMS) clinicaltrials.gov\/show\/NCT02959658"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1212\/NXI.0000000000000327","article-title":"Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study","volume":"4","author":"Davis","year":"2017","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Annals of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD012186.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jamaneurol.2015.2154","article-title":"Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial","volume":"72","author":"Cohen","year":"2015","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0128|cit128","doi-asserted-by":"crossref","unstructured":"Cohen J Belova A Selmaj K Wolf C Sormani MP Obery\u00e9 J Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone\u00ae (Teva) in subjects with relapsing remitting multiple sclerosis followed by an open-label 15 month GTR treatment part evaluating the long-term GTR treatment effects JAMA Neurology 2015 72 12 1433 41. Clinical trial protocol (version 4.0); p. 1-64","DOI":"10.1001\/jamaneurol.2015.2154"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0129|cit129","unstructured":"Efficacy and safety of GTR in comparison to Copaxone\u00ae (GATE) clinicaltrials.gov\/show\/NCT01489254"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0130|cit130","volume-title":"Clinical controlled randomized trial of azathioprine in multiple sclerosis","author":"Ghezzi","year":"1989"},{"issue":"12","key":"10.1002\/14651858.CD012186.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00415-017-8642-5","article-title":"Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month,open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)","volume":"264","author":"Comi","year":"2017","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0132|cit132","unstructured":"Fingolimod versus interferon beta 1b in cognitive symptoms (cognition) clinicaltrials.gov\/show\/NCT01333501"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/WNL.41.1.20","article-title":"The efficacy of azathioprine in relapsing-remitting multiple sclerosis","volume":"41","author":"Goodkin","year":"1991","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.410370108","article-title":"Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis","volume":"37","author":"Goodkin","year":"1995","journal-title":"Annals of Neurology"},{"issue":"9350","key":"10.1002\/14651858.CD012186.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0137|cit137","unstructured":"A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis clinicaltrials.gov\/show\/NCT00097188"},{"issue":"9440","key":"10.1002\/14651858.CD012186.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012186.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1177\/135245850000602S08","article-title":"ESIMS--an ongoing clinical trial in secondary progressive multiple sclerosis","volume":"6","author":"Hommes","year":"2000","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group","volume":"43","author":"IFNB","year":"1993","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.59.5.679","article-title":"Benefit of interferon beta-1a on MSFC progression in secondary progressive MS","volume":"59","author":"Cohen","year":"2002","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1177\/1352458510362442","article-title":"Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis","volume":"16","author":"De Stefano","year":"2010","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0143|cit143","unstructured":"A study to evaluate Rebif\u00ae new formulation (interferon-beta-1a) in relapsing remitting multiple sclerosis (IMPROVE) clinicaltrials.gov\/show\/NCT00441103"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","article-title":"Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)","volume":"359","author":"Durelli","year":"2002","journal-title":"Lancet"},{"issue":"15 Supplement","key":"10.1002\/14651858.CD012186.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"P1.387","DOI":"10.1212\/WNL.90.15_supplement.P1.387","article-title":"Analysis of lymphocyte counts and infection rates with fingolimod in patients with primary progressive multiple sclerosis over the INFORMS trial","volume":"90","author":"Fox","year":"2018","journal-title":"Neurology"},{"issue":"10023","key":"10.1002\/14651858.CD012186.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0147|cit147","unstructured":"This was an open-label, single-arm extension study (CFTY720D2306E1) to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study (CFTY720D2306) in PPMS. (INFORMS) clinicaltrials.gov\/show\/NCT00731692"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"12 Suppl 5","key":"10.1002\/14651858.CD012186.pub2-BIB0149|cit149","first-page":"S46","article-title":"Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]","volume":"57","author":"Johnson","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.50.3.701","article-title":"Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group","volume":"50","author":"Johnson","year":"1998","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD012186.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0152|cit152","unstructured":"Efficacy and safety of FTY720 in patients with relapsing multiple sclerosis clinicaltrials.gov\/show\/NCT00333138"},{"issue":"9648","key":"10.1002\/14651858.CD012186.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0154|cit154","unstructured":"Efficacy and safety of BG00012 in MS ClinicalTrials.gov\/show\/ NCT00168701"},{"issue":"9805","key":"10.1002\/14651858.CD012186.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis:a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0156|cit156","unstructured":"A study of the efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis clinicaltrials.gov\/show\/NCT00676715"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/jir.1993.13.333","article-title":"Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up","volume":"13","author":"Knobler","year":"1993","journal-title":"Journal of Interferon & Cytokine Research"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/01.wnl.0000204018.52311.ec","article-title":"A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis","volume":"66","author":"Koch-Henriksen","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1212\/WNL.60.1.44","article-title":"Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial","volume":"60","author":"Leary","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1468-1331.2002.00500.x","article-title":"No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment","volume":"9","author":"Lewanska","year":"2002","journal-title":"European Journal of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD012186.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/jnnp.54.12.1055","article-title":"Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study","volume":"54","author":"Likosky","year":"1991","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0162|cit162","unstructured":"Multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis www.clinicaltrialsregister.eu\/ctr-search\/search?query=2006-004937-13"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0163|cit163","doi-asserted-by":"crossref","unstructured":"Massacesi L Tramacere I Amoroso S Battaglia MA Benedetti MD Filippini G Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial PLoS One 2014 9 11 e113371. Tables S1 and S2; p. 1 3","DOI":"10.1371\/journal.pone.0113371"},{"issue":"11","key":"10.1002\/14651858.CD012186.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"e113371","DOI":"10.1371\/journal.pone.0113371","article-title":"Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial","volume":"9","author":"Massacesi","year":"2014","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0165|cit165","doi-asserted-by":"crossref","unstructured":"Massacesi L Tramacere I Amoroso S Battaglia MA Benedetti MD Filippini G Multicenter randomized controlled study of Azathioprine versus Interferon beta in relapsing-remitting multiple sclerosis PLoS One 2014 9 11 e113371. Study protocol; p. 1 32","DOI":"10.1371\/journal.pone.0113371"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0166|cit166","first-page":"86","article-title":"Assessment of fingolimod versus dimethyl fumarate for the treatment of multiple sclerosis; a 24-month follow-up study","volume":"10","author":"Masjedi","year":"2021","journal-title":"American Journal of Clinical and Experimental Immunology"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00838165","article-title":"A double blind study on azathioprine efficacy in multiple sclerosis: final report","volume":"240","author":"Milanese","year":"1993","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004150050066","article-title":"Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome","volume":"244","author":"Millefiorini","year":"1997","journal-title":"Journal of Neurology"},{"issue":"7169","key":"10.1002\/14651858.CD012186.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(61)91308-3","article-title":"Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin","volume":"1","author":"Miller","year":"1961","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD012186.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0172|cit172","unstructured":"Ofatumumab subcutaneous administration in subjects with relapsing-remitting multiple sclerosis (MIRROR) clinicaltrials.gov\/show\/NCT01457924"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0173|cit173","first-page":"P048","article-title":"Follow-up data from the Mirror study: A dose-ranging study of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis","volume":"20","author":"Sorenson","year":"2014","journal-title":"Multiple Sclerosis"},{"issue":"1-2","key":"10.1002\/14651858.CD012186.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jns.2014.01.038","article-title":"Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial","volume":"342","author":"Mokhber","year":"2014","journal-title":"Journal of the Neurological Sciences"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1177\/1352458509106937","article-title":"A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis","volume":"15","author":"Montalban","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clineuro.2007.01.007","article-title":"The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolate syndromes (CIS) suggestive of multiple sclerosis","volume":"109","author":"Motamed","year":"2007","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12883-020-01645-z","article-title":"Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial","volume":"20","author":"Albert","year":"2020","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0178|cit178","doi-asserted-by":"crossref","unstructured":"Albert C Mikolajczak J Liekfeld A Piper SK Scheel M Zimmermann HG Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial BMC Neurology 2020;20(1):75. 2020 20 1 75. Additional file 1 Supplementary methods and results; p. 1 14","DOI":"10.1186\/s12883-020-01645-z"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0179|cit179","unstructured":"MOdification of VIsual Outcomes after Optic Neuritis in CIS or MS by Gilenya (MOVING Study) clinicaltrials.gov\/show\/NCT01647880"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","article-title":"Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study","volume":"63","author":"Panitch","year":"2004","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD012186.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.55.8.1135","article-title":"IV immunoglobulin does not reverse established weakness in MS","volume":"55","author":"Noseworthy","year":"2000","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses","volume":"66","author":"O'Connor","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0185|cit185","unstructured":"A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS) clinicaltrials.gov\/show\/NCT00087529"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/1352458512459685","article-title":"EDSS variability before randomization may limit treatment discovery in primary progressive MS","volume":"19","author":"Zhang","year":"2013","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0187|cit187","first-page":"878","article-title":"Infusion-related reactions with OCRELIZUMAB in phase III studies","volume":"23","author":"De Seze","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0189|cit189","unstructured":"A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis clinicaltrials.gov\/show\/NCT01247324"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0191|cit191","unstructured":"A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis clinicaltrials.gov\/show\/NCT01412333"},{"issue":"7 Supplement","key":"10.1002\/14651858.CD012186.pub2-BIB0192|cit192","first-page":"P07.114","article-title":"Oral cladribine delays time to conversion to clinically definite MS in patients with a first demyelinating event: top line results from the phase III ORACLE MS Study","volume":"80","author":"Leist","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0194|cit194","unstructured":"Oral cladribine in early multiple sclerosis (MS) (ORACLE MS) clinicaltrials.gov\/show\/NCT00725985"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0195|cit195","first-page":"658","article-title":"Effect of OCRELIZUMAB on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study","volume":"23","author":"Fox","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0197|cit197","unstructured":"A study of Ocrelizumab in participants with primary progressive multiple sclerosis clinicaltrials.gov\/show\/NCT01194570"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1212\/WNL.53.4.679","article-title":"Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group","volume":"53","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1600-0404.2007.00813.x","article-title":"Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event","volume":"115","author":"Pakdaman","year":"2007","journal-title":"Acta Neurologica Scandinavica"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458507078400","article-title":"Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study","volume":"13","author":"Pohlau","year":"2007","journal-title":"Multiple Sclerosis"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1212\/01.WNL.0000154520.48391.69","article-title":"Treatment with laquinimod reduces development of active MRI lesions in relapsing MS","volume":"64","author":"Polman","year":"2005","journal-title":"Neurology"},{"issue":"9700","key":"10.1002\/14651858.CD012186.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0203|cit203","unstructured":"Evaluate early glatiramer acetate treatment in delaying conversion to clinically definite multiple sclerosis of subjects presenting with clinically isolated syndrome (PreCISe) clinicaltrials.gov\/show\/NCT00666224"},{"issue":"9139","key":"10.1002\/14651858.CD012186.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"e0168834. Proto","DOI":"10.1371\/journal.pone.0168834","article-title":"Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis","volume":"12","author":"Brochet","year":"2017","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0206|cit206","unstructured":"Efficacy of cyclophosphamide versus methylprednisolone in patients with secondary progressive multiple sclerosis (PROMESS) clinicaltrials.gov\/show\/NCT00241254"},{"issue":"15 Supplement","key":"10.1002\/14651858.CD012186.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"P3.410","DOI":"10.1212\/WNL.90.15_supplement.P3.410","article-title":"Clinical and magnetic resonance imaging results from Radiance Part B, a multicenter, randomized, double-blind, phase 3 trial of Ozanimod versus intramuscular Interferon \u03b2-1a in relapsing multiple sclerosis (RMS)","volume":"90","author":"Cohen","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD012186.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0209|cit209","unstructured":"Efficacy and safety study of ozanimod in relapsing multiple sclerosis (RADIANCE) clinicaltrials.gov\/show\/NCT02047734"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial","volume":"11","author":"Comi","year":"2012","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0211|cit211","unstructured":"REbif FLEXible dosing in early multiple sclerosis (MS) (REFLEX) clinicaltrials.gov\/show\/NCT00404352"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0212|cit212","unstructured":"RNF and Betaseron\u00ae Tolerability Study (REFORMS) clinicaltrials.gov\/show\/NCT00428584"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1471-2377-12-154","article-title":"Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferon\u03b2-1a versus subcutaneous interferon\u03b2-1b: results of the randomized, multicenter, Phase IIIb REFORMS study","volume":"12","author":"Singer","year":"2012","journal-title":"BMC Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0215|cit215","unstructured":"Rebif\u00ae versus Copaxone\u00ae in the treatment of relapsing remitting multiple sclerosis clinicaltrials.gov\/show\/NCT00078338"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0216|cit216","first-page":"e038861. Online","article-title":"Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study","volume":"10","author":"Butzkueven","year":"2020","journal-title":"British Medical Journal Open"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0217|cit217","unstructured":"Impact of Natalizumab versus Fingolimod in relapsing-remitting multiple sclerosis (RRMS) participants (REVEAL) clinicaltrials.gov\/show\/NCT02342704"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0218|cit218","unstructured":"Efficacy and safety of FTY720 in patients with relapsing multiple sclerosis (MS) clinicaltrials.gov\/show\/NCT00537082"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1177\/1352458511435984","article-title":"A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis","volume":"18","author":"Saida","year":"2012","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0220|cit220","unstructured":"Natalizumab (BG00002, Tysabri) study in Japanese participants with relapsing-remitting multiple sclerosis (RRMS) (Tysabri Japan) clinicaltrials.gov\/show\/NCT01440101"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.msard.2016.11.002","article-title":"Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study","volume":"11","author":"Saida","year":"2017","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"9884","key":"10.1002\/14651858.CD012186.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0223|cit223","unstructured":"Safety and efficacy study of daclizumab high yield process (DAC HYP) to treat relapsing-remitting multiple sclerosis (SELECT) clinicaltrials.gov\/show\/NCT00390221"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2016.02.001","article-title":"Assessing the impact of multiple sclerosis disease activity and DACLIZUMAB HYP treatment on patient-reported outcomes: Results from the SELECT trial","volume":"6","author":"Phillips","year":"2016","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"11","key":"10.1002\/14651858.CD012186.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results","volume":"56","year":"2001","journal-title":"Neurology"},{"issue":"15 Supplement","key":"10.1002\/14651858.CD012186.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"P3.396","DOI":"10.1212\/WNL.90.15_supplement.P3.396","article-title":"Ozanimod demonstrates efficacy and safety in a multicenter, randomized, double-blind, double-dummy, active-controlled phase 3 trial of relapsing multiple sclerosis (SUNBEAM)","volume":"90","author":"Comi","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD012186.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurology"},{"issue":"15 Supplement","key":"10.1002\/14651858.CD012186.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"S36.006","DOI":"10.1212\/WNL.90.15_supplement.S36.006","article-title":"Safety of Ozanimod versus Interferon \u03b2-1a in two multicenter, randomized, double-blind, parallel-group, active-controlled, double-dummy phase 3 studies in relapsing multiple sclerosis (SUNBEAM and RADIANCE Part B)","volume":"90","author":"Cree","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0229|cit229","unstructured":"Study of ozanimod (RPC1063) in relapsing multiple sclerosis (MS) (SUNBEAM) clinicaltrials.gov\/show\/NCT02294058"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0230|cit230","unstructured":"Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO) ClinicalTrials.gov\/show\/NCT00134563"},{"issue":"14","key":"10.1002\/14651858.CD012186.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012186.pub2-BIB0232|cit232","first-page":"16","article-title":"Teriflunomide significantly slows brain volume loss in MS patients irrespective of disability progression","volume":"86","author":"Sprenger","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0233|cit233","unstructured":"A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE) clinicaltrials.gov\/show\/NCT00883337"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Multiple Sclerosis"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0236|cit236","unstructured":"Phase III study with Teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC) clinicaltrials.gov\/show\/NCT00622700"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"205521731877523","DOI":"10.1177\/2055217318775236","article-title":"Clinical efficacy of Teriflunomide over a fixed 2-year duration in the TOWER study","volume":"4","author":"Freedman","year":"2018","journal-title":"Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00415-014-7395-7","article-title":"Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study","volume":"261","author":"Miller","year":"2014","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jocn.2018.09.012","article-title":"Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: a subgroup analysis of the phase 3 TOWER study","volume":"59","author":"Miller","year":"2019","journal-title":"Journal of Clinical Neuroscience"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0241|cit241","unstructured":"An efficacy study of Teriflunomide in participants with relapsing multiple sclerosis (TOWER) clinicaltrials.gov\/show\/NCT00751881"},{"issue":"23","key":"10.1002\/14651858.CD012186.pub2-BIB0242|cit242","first-page":"2776","article-title":"Efficacy and safety of teriflunomide in Chinese patients with relapsing forms of multiple sclerosis: a subgroup analysis of the phase 3 TOWER study","volume":"131","author":"Qiu","year":"2018","journal-title":"Chinese Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0244|cit244","unstructured":"Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis with optional extension phase (TRANSFORMS) clinicaltrials.gov\/show\/NCT00340834"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.53.3.466","article-title":"The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group","volume":"53","author":"Tubridy","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0246|cit246","first-page":"210","article-title":"A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis","volume":"101","author":"de Wyngaert","year":"2001","journal-title":"Acta Neurologica Belgica"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1212\/WNL.88.16_supplement.P2.354","article-title":"Disability progression and cerebrospinal fluid status in PPMS: Re-analysis of the ProMiSe clinical trial data set","volume":"88","author":"Steinerman","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ana.21079","article-title":"Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0249|cit249","doi-asserted-by":"crossref","unstructured":"A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administereddaily in subjects with relapsing remitting multiple sclerosis (RRMS) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-011234-99\/DE","DOI":"10.1016\/S0513-5117(09)79049-0"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"172. Additional","DOI":"10.1186\/s12974-017-0945-z","article-title":"Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS","volume":"14","author":"Ziemssen","year":"2017","journal-title":"Journal of Neuroinflammation"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0251|cit251","first-page":"NP14","article-title":"Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis","volume":"24","author":"Barkhof","year":"2018","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1073\/pnas.93.4.1716","article-title":"The treatment of chronic progressive multiple sclerosis with cladribine","volume":"93","author":"Beutler","year":"1996","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11055-018-0643-z","article-title":"Comparative placebo-controlled clinical trial of the efficacy and safety of Interferon \u03b2-1a formulations for S.C. administration in patients with remitting multiple sclerosis: first-year results","volume":"48","author":"Boiko","year":"2018","journal-title":"Neuroscience and Behavioral Physiology"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"73","DOI":"10.17116\/jnevro20191192273","article-title":"Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment na\u00efve patients with remitting multiple sclerosis, who have not received DMT, after switching from other Interferon \u03b2-1a","volume":"119","author":"Boyko","year":"2019","journal-title":"Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova"},{"issue":"2. Vyp. 2","key":"10.1002\/14651858.CD012186.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"73","DOI":"10.17116\/jnevro20191192273","article-title":"Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment na\u00efve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon \u03b2-1a","volume":"119","author":"Boyko","year":"2019","journal-title":"Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"100","DOI":"10.17116\/jnevro2019119102100","article-title":"The new pegylated Interferon beta-1a (sampegInterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis","volume":"119","author":"Boyko","year":"2019","journal-title":"Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"62","DOI":"10.17116\/jnevro202212201162","article-title":"Efficacy and safety of sampeginterferon \u03b2-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial","volume":"122","author":"Boyko","year":"2022","journal-title":"Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/01.wnl.0000341934.12142.74","article-title":"Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS","volume":"72","author":"Cohen","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0259|cit259","first-page":"48","article-title":"Evaluating the efficacy and safety of 6-week extended interval dosing of Natalizumab via a prospective, controlled, randomized phase 3B study","volume":"25","author":"Cohen","year":"2019","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0260|cit260","first-page":"212","article-title":"Baseline characteristics of multiple sclerosis patients enrolled in NOVA, a multicentre, randomised trial to assess the efficacy of Natalizumab every-6-weeks dosing","volume":"27","author":"Foley","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0261|cit261","unstructured":"A study to evaluate efficacy, safety, and tolerability of EID of Natalizumab (BG00002) in participants with RRMS switching from treatment with Natalizumab SID in relation to continued SID treatment- followed by extension study comprising sc and iv Natalizumab administration ClinicalTrials.gov\/show\/NCT03689972"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ana.22316","article-title":"Phase III dose-comparison study of glatiramer acetate for multiple sclerosis","volume":"69","author":"Comi","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(06)70327-1","article-title":"Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study","volume":"5","author":"Filippi","year":"2006","journal-title":"The Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0265|cit265","unstructured":"A randomized, open-label, dose-ranging study to evaluate the pharmacokinetics and initial safety of subcutaneous and intramuscular Natalizumab in subjects with multiple sclerosis ClinicalTrials.gov\/show\/NCT00559702"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.707","article-title":"A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis","volume":"56","author":"Plavina","year":"2016","journal-title":"Journal Of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria","volume":"62","author":"Edan","year":"1997","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.msard.2014.06.005","article-title":"Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis","volume":"3","author":"Fox","year":"2014","journal-title":"Multiple Sclerosis And Related Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0269|cit269","unstructured":"A 6-month, randomized, open-label, patient outcomes, safety and tolerability study of fingolimod (FTY720) 0.5 mg\/day vs. comparator in patients with relapsing forms of multiple sclerosis (EPOC) ClinicalTrials.gov\/show\/NCT01216072"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0270|cit270","unstructured":"A study of ALKS 8700 in adults with relapsing remitting multiple sclerosis (MS) EVOLVE-MS-1 ClinicalTrials.gov: NCT02634307"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","article-title":"Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study","volume":"39","author":"Wray","year":"2022","journal-title":"Advances In Therapy"},{"issue":"23","key":"10.1002\/14651858.CD012186.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e318258f7d4","article-title":"Teriflunomide added to interferon- in relapsing multiple sclerosis: a randomized phase II trial","volume":"78","author":"Freedman","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2055217315618687","article-title":"A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis","volume":"1","author":"Freedman","year":"2015","journal-title":"Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2377-13-101","article-title":"Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial","volume":"13","author":"Gobbi","year":"2013","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0275|cit275","unstructured":"Natalizumab de-escalation with Interferon beta-1b ClinicalTrials.gov\/show\/NCT01144052"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2377-14-38","article-title":"Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon \u03b2","volume":"14","author":"Zecca","year":"2014","journal-title":"BMC Neurology"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"Glance: Results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1212\/NXI.0000000000000807","article-title":"Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS","volume":"7","author":"Hartung","year":"2020","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0279|cit279","first-page":"334","article-title":"Safety of Ocrelizumab in Multiple sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple sclerosis","volume":"25","author":"Hauser","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD012186.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/1352458509105229","article-title":"Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis","volume":"15","author":"Havrdova","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bcp.12968","article-title":"COMPARE: Pharmacokinetic profiles of subcutaneous pegINTERFERON beta-1a and subcutaneous INTERFERON beta-1a over 2 weeks in healthy subjects","volume":"82","author":"Hu","year":"2016","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD012186.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0284|cit284","unstructured":"A phase 2 study of Atacicept in subjects with relapsing multiple sclerosis (ATAMS) ClinicalTrials.gov\/show\/NCT00642902"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","article-title":"Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study","volume":"73","author":"Kappos","year":"2016","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0286|cit286","unstructured":"Long-term safety, tolerability and efficacy of BAF312 given orally in patients with relapsing-remitting multiple sclerosis ClinicalTrials.gov\/show\/NCT01185821"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD012186.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.40.3_Part_1.479","article-title":"Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation","volume":"40","author":"Kastrukoff","year":"1990","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/archneurol.2010.222","article-title":"A randomized controlled double masked trial of albuterol add-on therapy in patients with multiple sclerosis","volume":"67","author":"Khoury","year":"2010","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/acn3.293","article-title":"Insufficient disease inhibition by intrathecal RITUXIMAB in progressive multiple sclerosis","volume":"3","author":"Komori","year":"2016","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0290|cit290","unstructured":"Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe) ClinicalTrials.gov\/show\/NCT01212094"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): A randomised, controlled, double-blind, non-inferiority trial","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0292|cit292","unstructured":"Efficacy and safety of Methylprednisolone per os versus iv for the treatment of multiple sclerosis (MS) relapses (COPOUSEP) ClinicalTrials.gov\/show\/NCT00984984"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"25","key":"10.1002\/14651858.CD012186.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Evobrutinib phase 2 study group. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0296|cit296","unstructured":"A study of efficacy and safety of M2951 in participants with relapsing multiple sclerosis ClinicalTrials.gov\/show\/NCT02975349"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0297|cit297","unstructured":"An efficacy and safety comparison study of two marketed drugs in patients with relapsing-remitting MS (ABOVE) ClinicalTrials.gov\/show\/NCT00206648"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0298|cit298","unstructured":"Study evaluating Rebif, Copaxone, and Tysabri for active multiple sclerosis (SURPASS) ClinicalTrials.gov\/show\/NCT01058005"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0299|cit299","unstructured":"Impact study of 2 therapeutic strategy for aggressive remitting multiple sclerosis (IQUALYSEP) ClinicalTrials.gov\/show\/NCT01065727"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0300|cit300","unstructured":"Using optical coherence tomography (OCT) to evaluate the efficacy and safety of Pegylated Interferon beta-1a (BIIB017) in patients with relapsing multiple sclerosis ClinicalTrials.gov\/show\/NCT01337427"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s40120-019-00159-2","article-title":"Efficacy and safety of alemtuzumab in patients of African descent with relapsing-remitting multiple sclerosis: 8-year follow-up of CARE MS I and II (TOPAZ study)","volume":"8","author":"Okai","year":"2019","journal-title":"Neurology and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12883-019-1337-z","article-title":"Outcomes of Natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: A prespecified 2-year interim analysis of STRIVE","volume":"19","author":"Perumal","year":"2019","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.msard.2018.07.014","article-title":"Treatment retention on Fingolimod compared with injectable multiple sclerosis therapies in African-American patients: a subgroup analysis of a randomized phase 4 study","volume":"25","author":"Cascione","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0304|cit304","first-page":"322","article-title":"Confirmed disability improvement in patients treated with FINGOLIMOD in phase 3 and extension trial programmes for up to 96 months","volume":"23","author":"Cree","year":"2017","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"175628641877433","DOI":"10.1177\/1756286418774338","article-title":"Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial.","volume":"11","author":"Cree","year":"2018","journal-title":"Therapeutic Advances In Neurological Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0306|cit306","unstructured":"Evaluation of patient retention of Fingolimod vs. currently approved disease modifying therapy in patients with relapsing remitting multiple sclerosis. (PREFERMS) ClinicalTrials.gov\/show\/NCT01623596"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"e30618","DOI":"10.5812\/ircmj.30618","article-title":"Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone: a double blind randomized controlled clinical trial","volume":"17","author":"Rahimdel","year":"2015","journal-title":"Iranian Red Crescent Medical Journal"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0308|cit308","unstructured":"Oral corticotherapy in megadoses to treat multiple sclerosis during relapse ClinicalTrials.gov\/show\/NCT00753792"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/1352458513508835","article-title":"A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS","volume":"20","author":"Ramo-Tello","year":"2014","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1352458515590648","article-title":"Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses","volume":"22","author":"Ramo-Tello","year":"2016","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0311|cit311","first-page":"1491\u20138","article-title":"MS disease activity in RESTORE. A randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology 2014;82:"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0312|cit312","unstructured":"Treatment interruption of Natalizumab (RESTORE) ClinicalTrials.gov\/show\/NCT01071083"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","article-title":"Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0314|cit314","unstructured":"A phase IV study of Rebif \u00ae 44mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone (REMAIN) ClinicalTrials.gov\/show\/NCT01142466"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285611428503","article-title":"Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis","volume":"5","author":"Rieckmann","year":"2012","journal-title":"Therapeutic Advances In Neurological Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/acn3.293","article-title":"Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis","volume":"3","author":"Komori","year":"2016","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0317|cit317","unstructured":"Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe) clinicaltrials.gov\/show\/NCT01212094"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1525-1381.1999.09115.x","article-title":"A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis","volume":"111","author":"Romine","year":"1999","journal-title":"Proceedings of the Association of American Physicians"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.msard.2016.02.002","article-title":"Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis","volume":"7","author":"Saida","year":"2016","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1474-4422(14)70039-0","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial","volume":"13","author":"Giovannoni","year":"2014","journal-title":"The Lancet. Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12883-016-0635-y","article-title":"Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study","volume":"16","author":"Gold","year":"2016","journal-title":"BMC Neurology"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-020-09835-y","article-title":"Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study","volume":"267","author":"Gold","year":"2020","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40120-016-0048-2","article-title":"Pregnancy experience: nonclinical studies and pregnancy outcomes in the daclizumab clinical study program","volume":"5","author":"Gold","year":"2016","journal-title":"Neurology and Therapy"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0324|cit324","unstructured":"Safety and efficacy extension study of daclizumab high yield process (DAC HYP) in participants with multiple sclerosis who have completed study 205MS201 (NCT00390221) to treat relapsing-remitting multiple sclerosis (SELECTION) ClinicalTrials.gov\/show\/NCT00870740"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0325|cit325","unstructured":"Safety and efficacy extension study of daclizumab high yield process (DAC HYP) (BIIB019) in participants who have completed study 205MS202 (NCT00870740) to treat relapsing remitting multiple sclerosis (SELECTED) ClinicalTrials.gov\/show\/NCT01051349"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0326|cit326","unstructured":"Safety and efficacy of Natalizumab in combination with Avonex in the treatment of multiple sclerosis ClinicalTrials.gov\/show\/NCT00030966"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"8914","key":"10.1002\/14651858.CD012186.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0329|cit329","unstructured":"Ofatumumab dose-finding in relapsing remitting multiple sclerosis (RRMS) patients (OMS115102) clinicaltrials.gov\/show\/NCT00640328"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","article-title":"Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study","volume":"82","author":"Sorensen","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7224\/1537-2073.2015-024","article-title":"Laquinimod safety profile: pooled analyses from the ALLEGRO and BRAVO trials","volume":"19","author":"Sorensen","year":"2017","journal-title":"International Journal of MS Care"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0332|cit332","first-page":"221","article-title":"The effect of cladribine on some parameters of blood and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis (RR-MS)","volume":"55","author":"Stelmasiak","year":"2000","journal-title":"Annales Universitatis Mariae Curie-Sklodowska"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of Rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0334|cit334","first-page":"49","article-title":"A randomized, blinded, parallel-group phase-2 study exploring the efficacy, safety, and tolerability of multiple natalizumab dosing regimens in patients with relapsing multiple sclerosis (REFINE)","volume":"22","author":"Trojano","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis","volume":"266","author":"Turner","year":"2019","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0336|cit336","unstructured":"Safety and tolerability of Glatiramer acetate (GLACIER) ClinicalTrials.gov\/show\/NCT01874145"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.msard.2015.06.005","article-title":"GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis","volume":"4","author":"Wolinsky","year":"2015","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/WNL.84.14_supplement.P7.218","article-title":"Patient experience with glatiramer acetate 40 mg\/1 ml three-times weekly treatment for relapsing-remitting multiple sclerosis: Results from the GLACIER extension study","volume":"84","author":"Wynn","year":"2015","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD012186.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458518796675","article-title":"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","volume":"25","author":"Wray","year":"2019","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0340|cit340","unstructured":"Study of subcutaneous Daclizumab in patients with active, relapsing forms of multiple sclerosis ClinicalTrials.gov\/show\/NCT00109161"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2010","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0342|cit342","unstructured":"A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with relapsing forms of MS to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000284-93\/EE\/"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0343|cit343","unstructured":"A study to evaluate the efficacy and safety of Ocrelizumab in adults with primary progressive multiple sclerosis (O'HAND) ClinicalTrials.gov\/show\/NCT04035005"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0344|cit344","unstructured":"Norwegian study of oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) ClinicalTrials.gov\/show\/NCT04121403"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0345|cit345","unstructured":"Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) ClinicalTrials.gov\/show\/NCT04578639"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0346|cit346","unstructured":"Non-inferiority study of Ocrelizumab and Rituximab in active Multiple Sclerosis (DanNORMS) ClinicalTrials.gov\/show\/NCT04688788"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0347|cit347","unstructured":"ChariotMS - Cladribine to halt deterioration in people with advanced multiple sclerosis (ChariotMS) ClinicalTrials.gov\/show\/NCT04695080"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0348|cit348","unstructured":"Open label randomized multicenter to assess efficacy & tolerability of Ofatumumab 20mg vs. first line DMT in RMS (STHENOS) ClinicalTrials.gov\/show\/NCT04788615"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0349|cit349","unstructured":"A multicenter study of continued current therapy vs transition to Ofatumumab after neurofilament (NFL) elevation (SOSTOS) ClinicalTrials.gov\/show\/NCT05090371"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0350|cit350","unstructured":"Reducing the frequency of autoimmune adverse events in the treatment of multiple sclerosis with alemtuzumab using B-cell depletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12621001502820 2021"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40263-015-0238-y","article-title":"Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs","volume":"29","author":"Amato","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jclinepi.2008.03.004","article-title":"Attention should be given to multiplicity issues in systematic reviews","volume":"61","author":"Bender","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1756285614564152","article-title":"Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview","volume":"8","author":"Bomprezzi","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1212\/WNL.0000000000003345","article-title":"Rituximab for treating multiple sclerosis: off-label but on target","volume":"87","author":"Bourdette","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2021.07.011","article-title":"GRADE guidelines 33: Addressing imprecision in a network meta-analysis","volume":"139","author":"Brignardello-Petersen","year":"2021","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in Stata","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0358|cit358","volume-title":"In: Armitage P, Colton T (editors). Encyclopedia of Biostatistics (2nd edition)","author":"Chen","year":"2005"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msard.2015.02.004","article-title":"Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients","volume":"4","author":"Chouhfeh","year":"2015","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"Issue 7-8","key":"10.1002\/14651858.CD012186.pub2-BIB0361|cit361","first-page":"932","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"Volume 29","author":"Dias","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1756285615598910","article-title":"Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis","volume":"8","author":"Farber","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0363|cit363","unstructured":"CFR - Code of Federal Regulations Title 21 www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0364|cit364","unstructured":"Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling https:\/\/www.federalregister.gov\/articles\/2014\/12\/04\/2014-28241\/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0365|cit365","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008933.pub2","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","author":"Filippini","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00228-012-1383-6","article-title":"Placebo? no thanks, it might be bad for me!","volume":"69","author":"Garattini","year":"2013","journal-title":"European Journal of Clininical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hir.12269","article-title":"Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study","volume":"36","year":"2019","journal-title":"Health Information & Libraries Journal"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hir.12251","article-title":"Development of a search filter to identify reports of controlled clinical trials within CINAHL Plus","volume":"36","year":"2019","journal-title":"Health Information & Libraries Journal"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0369|cit369","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Goodman","year":"2006"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"88","DOI":"10.14740\/jocmr3168w","article-title":"A multiple treatment comparison of eleven disease-modifying drugs used for multiple sclerosis","volume":"10","author":"Hamidi","year":"2918","journal-title":"Journal of Clinical Medicine Research"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/13524585211033190","article-title":"Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis","volume":"27","author":"Hartung","year":"2021","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0373|cit373","unstructured":"Higgins J Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0374|cit374","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Introductory guide MedDRA version 18.0 http:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_18_0_english.pdf"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"21","key":"10.1002\/14651858.CD012186.pub2-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random inconsistency effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"782","DOI":"10.2471\/BLT.16.174326","article-title":"Use of networkmeta-analysis in clinical guidelines","volume":"94","author":"Kanters","year":"2016","journal-title":"Bulletin of the World Health Organization"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0379|cit379","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). The Cochrane Collaboration, 2022 Available from training.cochrane.org\/handbook"},{"issue":"12","key":"10.1002\/14651858.CD012186.pub2-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"267","author":"Li","year":"2020","journal-title":"Journal of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD012186.pub2-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00415-020-09913-1","article-title":"A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project","volume":"267","author":"Lopez-Leon","year":"2020","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.msard.2019.06.036","article-title":"Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis","volume":"35","author":"Lucchetta","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"6","key":"10.1002\/14651858.CD012186.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/1756285615605429","article-title":"Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes","volume":"8","author":"Lycke","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2007.06.009","article-title":"A highly sensitive search strategy for clinical trials in Literatura Latino Americana e do Caribe em Ci\u00eancias da Sa\u00fade (LILACS) was developed","volume":"61","author":"Manr\u00edquez Juan","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying Randomized Controlled Trials: An evaluation and practitioner's guide","volume":"9","author":"Marshall Iain","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ana.410440415","article-title":"Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction","volume":"44","author":"Mart\u00ednez-C\u00e1ceres","year":"1998","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0391|cit391","unstructured":"McDonald S Noel-Storr AH Thomas J Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews Global Evidence Summit; 2017 September 13-16; Cape Town, South Africa 2017"},{"issue":"1","key":"10.1002\/14651858.CD012186.pub2-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"76\u201386","DOI":"10.1177\/1536867X1401400106","article-title":"Indirect treatment comparison","volume":"14","author":"Miladinovic","year":"2014","journal-title":"Stata Journal"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0394|cit394","unstructured":"Multiple-Treatments Meta-analysis (MTM). A framework for evaluating and ranking multiple healthcare technologies http:\/\/www.mtm.uoi.gr\/"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"k585","DOI":"10.1136\/bmj.k585","article-title":"Living network meta-analysis compared withpairwise meta-analysis in comparative effectiveness research: empirical study","volume":"360","author":"Nikolakopoulou","year":"2018","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0396|cit396","first-page":"17","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"3","author":"Nikolakopoulou","year":"2020","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0397|cit397","unstructured":"Noel-Storr AH and the Project Transform Team Cochrane Crowd: new ways of working together to produce health evidence Evidence Live; 2018 June 18-20; Oxford, UK 2018"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0398|cit398","unstructured":"Peryer G Golder S Junqueira D Vohra S Loke YK Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org\/handbook"},{"issue":"10","key":"10.1002\/14651858.CD012186.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"292\u2013302","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012186.pub2-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s13311-020-00847-0","article-title":"Induction versus escalation in multiple sclerosis: A 10-year real world study","volume":"17","author":"Prosperini","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"17","key":"10.1002\/14651858.CD012186.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"80\u201397","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"18","key":"10.1002\/14651858.CD012186.pub2-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/cer-2020-0122","article-title":"Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis","volume":"9","author":"Samjoo","year":"2020","journal-title":"Journal of Comparative Effectiveness Research"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0410|cit410","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-Analysis with R","author":"Schwarzer","year":"2015"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0411|cit411","unstructured":"Sch\u00fcnemann H Oxman A Higgins J Vist G Glasziou P Guyatt G Chapter 11: Presenting results and \u2018Summary of findings\u2019 tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD012186.pub2-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2018","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/ane.13697","article-title":"Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis","volume":"146","author":"Silva","year":"2022","journal-title":"Acta Neurol Scandinavica"},{"issue":"7","key":"10.1002\/14651858.CD012186.pub2-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Current Treatment Options in Neurology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jclinepi.2017.08.011","article-title":"Living systematic reviews: 2. Combining human and machine effort","volume":"91","author":"Thomas","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0416|cit416","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub2","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012186.pub2-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD012186.pub2-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1536867X1101100206","article-title":"Multivariate random-effects meta-regression: updates to mvmeta","volume":"11","author":"White","year":"2011","journal-title":"The STATA Journal"},{"issue":"2","key":"10.1002\/14651858.CD012186.pub2-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"6 Neuroinfectio","key":"10.1002\/14651858.CD012186.pub2-BIB0421|cit421","first-page":"1577","article-title":"Central nervous system infections with immunomodulatory therapies","volume":"21","author":"Williamson","year":"2015","journal-title":"Continuum (Minneapolis Minn.)"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0422|cit422","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.msard.2018.08.026","article-title":"Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis","volume":"25","author":"Xu","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nu\u00f1ez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"175628641982654","DOI":"10.1177\/1756286419826547","article-title":"Evolution of clinical trials in multiple sclerosis","volume":"12","author":"Zhang","year":"2019","journal-title":"Therapeutic advances in neurological disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"175628642110064","DOI":"10.1177\/17562864211006499","article-title":"Disease-modifying therapy prescription patterns in people with multiple sclerosis by age","volume":"14","author":"Zhang","year":"2021","journal-title":"Therapeutic Advances In Neurological Disorders"},{"key":"10.1002\/14651858.CD012186.pub2-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD012186.pub2-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1007\/s10072-022-06197-3","article-title":"Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"43","author":"\u015aladowska","year":"2022","journal-title":"Neurological sciences"},{"issue":"5","key":"10.1002\/14651858.CD012186.pub2-BIB0428|cit428","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012186","article-title":"Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T03:08:07Z","timestamp":1746673687000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012186.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":428,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012186.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}